| アブストラクト | BACKGROUND: The association between pioglitazone (PLZ) and bladder cancer (BC) remains controversial in several randomized control trials, meta-analyses of multiple prospective studies, and large-scale observational studies. RESEARCH DESIGN AND METHODS: Adverse event (AE) data from 1 January 2004 to 31 March 2024 were extracted from the Food and Drug Administration Adverse Event Reporting System (FAERS) database. Disproportionality analysis were applied to quantify the signals of PLZ related BC. RESULTS: In total, 17,627,524 AE reports were recorded in the FAERS database, of which 1366 were PLZ-related BCs. More male than female patients were reported. The median age of patients was 70 years old. The peak in the annual report occurred in 2011. A total of 602 AEs reported time to onset (TTO) and the median TTO was 1023 days. In this study, BC and BC recurrence were strong signal, whereas BC stage 0 (with cancer in situ), stage ii and iii were weak signals. CONCLUSIONS: This study comprehensively demostrated the PLZ-induced risk of BC in patients with diabetes mellitus using the FAERS database. The results demonstrated that the patients treated with PLZ were more likely to develop BC. The male and aging attributed more cases to BC-related reports of PLZ treated patients. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| Pubmed追加日 | 2024/9/21 |
|---|
| 投稿者 | Chen, Hai-Yan; Zhao, Hui; Yang, Jun-Jie; Zhang, Qian; Yan, Ming-Ming; Qiu, Xiao-Yan |
|---|
| 組織名 | Department of Pharmacy, Affiliated Dongyang Hospital of Wenzhou Medical;University, Dongyang, Zhejiang, P. R. China.;Clinical Pharmacy Department, Huashan Hospital, Fudan University, Shanghai, P. R.;China.;Medical Affair Department, Affiliated Dongyang Hospital of Wenzhou Medical;University, Dongyang, Zhejiang, P. R .China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/39301684/ |
|---|
